randomisation schedule (AbbVie Inc)
90
Structured Review
AbbVie Inc
randomisation schedule
Randomisation Schedule, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisation+schedule/randomisation+schedule/10__1002_slash_14651858__cd014805__pub2-1574-1-13
Average 90 stars, based on 1 article reviews
Randomisation Schedule, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/randomisation+schedule/randomisation+schedule/10__1002_slash_14651858__cd014805__pub2-1574-1-13
Average 90 stars, based on 1 article reviews
randomisation schedule - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Generated:Article Title: Interventions for fatigue in inflammatory bowel disease Article Snippet: The patient number and group of each stratum were assigned by a central randomisation schedule generated by AbbVie (Chicago, IL, USA) using WebRando software for randomisation and ClinPhone, an interactive voice and web response system for patient allocation. .. The subject Article Title: Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial Article Snippet: .. Interactive response technology was used to assign patients a unique identification number at the screening visit based on a Article Title: Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial Article Snippet: Methods This study is a double-blind, placebo-controlled trial at 150 sites in 35 countries.. We enrolled patients aged 18 years or older with active rheumatoid arthritis for 3 months or longer, who had received csDMARDs for at least 3 months with a stable dose for at least 4 weeks before study entry, and had an inadequate response to at least one of the following csDMARDs: methotrexate, sulfasalazine, or leflunomide.. Using interactive response technology, we randomly assigned patients receiving stable background csDMARDs (2:2:1:1) to receive a once-daily extendedrelease formulation of upadacitinib 15 mg or 30 mg, or placebo, for 12 weeks. Sequencing:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote (p 2 & Appendix): "The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (p 2 & Appendix): "The Selection:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote (p 2 & Appendix): "The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Risk of bias Bias Authors' judgement Support for judgement Random sequence generation (selection bias) Low risk Quote (p 2 & Appendix): "The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: Random sequence generation (selection bias) , Low risk , Quote (p 2 & Appendix): "The randomisation schedule was prepared by the Statistics Department of AbbVie, US. Randomization was performed using an adequate block size.“ Comment: probably done. .. Allocation concealment (selection bias) , Low risk , Quote (p 2 & Appendix): “An interactive voice/web response system determined patient Blocking Assay:Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: .. Random sequence generation (selection bias) , Low risk , Quote (p 2 & Appendix): "The Article Title: Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis Article Snippet: Random sequence generation (selection bias) , Low risk , Quote (p 2 & Appendix): "The randomisation schedule was prepared by the Statistics Department of AbbVie, US. Randomization was performed using an adequate block size.“ Comment: probably done. .. Allocation concealment (selection bias) , Low risk , Quote (p 2 & Appendix): “An interactive voice/web response system determined patient |
